©
Dominic Chavez, World Bank
The study, published in The Lancet Infectious Diseases, has confirmed the safety and efficacy of single low-dose primaquine in reducing malaria transmission in young children, who bear the highest malaria burden globally.
This approach has mostly been used in older children and adults, as the tablets currently available are not easy to use in young children. The lack of a child-friendly formulation limits the potential of primaquine to play a role in global elimination efforts. This work also quantifies primaquine efficacy in areas with a high malaria burden, suggesting a potential role for the drug in limiting the selection and spread of drug-resistant malaria in Africa. And although young children account for over two-thirds of malaria deaths in Africa, a paediatric formulation of primaquine is not yet marketed.
Currently, the World Health Organization (WHO) recommends a single low dose of primaquine (0.25 mg/kg) only in areas with low malaria transmission. However, resistance to artemisinin—the main malaria treatment—is spreading, including in African regions with moderate-to-high transmission. Artemisinin (partial) resistance slows parasite clearance, leading to higher gametocyte levels and potentially increasing the spread of drug-resistant malaria.
Researchers, led by Dr Daniel Yilma of Jimma University in Ethiopia, conducted an individual patient data meta-analysis using data shared with the WWARN repository. Dr Yilma said ‘This is the first large-scale comparison of a single low-dose primaquine’s impact across different age groups and transmission settings.’
Prof Karen Barnes, University of Cape Town and the Lead for WWARN’s Antimalarial Resistance Theme, said: ‘This analysis demonstrates the potential of combining all available individual patient data to inform regulatory and policy decisions, saving the time and substantial expense of conducting new clinical trials in over 1000 young children.’
Read the full story on the Nuffield Department of Medicine website.